Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.

Kubo A, Hashimoto H, Takahashi N, Yamada Y.

World J Gastroenterol. 2016 Jan 14;22(2):887-94. doi: 10.3748/wjg.v22.i2.887. Review.

2.

Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G.

World J Gastroenterol. 2016 Jan 14;22(2):519-33. doi: 10.3748/wjg.v22.i2.519. Review.

3.

Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.

Kocoglu H, Velibeyoglu FM, Karaca M, Tural D.

World J Gastrointest Oncol. 2016 Jan 15;8(1):1-7. doi: 10.4251/wjgo.v8.i1.1. Review.

4.

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Wurz GT, Kao CJ, DeGregorio MW.

Ther Adv Med Oncol. 2016 Jan;8(1):4-31. doi: 10.1177/1758834015615514. Review.

5.

Colorectal Cancer: Basic and Translational Research.

Zhou JJ, Zheng S.

Gastrointest Tumors. 2013 Sep;1(1):18-24. doi: 10.1159/000354994. Epub 2013 Sep 12. Review.

6.

Integration of molecular pathology, epidemiology and social science for global precision medicine.

Nishi A, Milner DA Jr, Giovannucci EL, Nishihara R, Tan AS, Kawachi I, Ogino S.

Expert Rev Mol Diagn. 2016 Jan;16(1):11-23. doi: 10.1586/14737159.2016.1115346. Epub 2015 Dec 4.

PMID:
26636627
7.

Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.

Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, Boku N.

Mol Clin Oncol. 2015 Sep;3(5):1029-1034. Epub 2015 Jun 24.

8.

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC.

J Clin Invest. 2015 Dec;125(12):4529-43. doi: 10.1172/JCI82826. Epub 2015 Nov 16.

PMID:
26571401
9.

Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis.

Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM.

Ecancermedicalscience. 2015 Oct 15;9:582. doi: 10.3332/ecancer.2015.582. eCollection 2015. Review.

10.

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.

Trojan J, Mineur L, Tomášek J, Rouleau E, Fabian P, de Maglio G, García-Alfonso P, Aprile G, Taylor A, Kafatos G, Downey G, Terwey JH, van Krieken JH.

PLoS One. 2015 Oct 22;10(10):e0140717. doi: 10.1371/journal.pone.0140717. eCollection 2015.

11.

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.

Kim ST, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC.

BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y.

12.

Treatment of colorectal cancer in the elderly.

Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T.

World J Gastrointest Oncol. 2015 Oct 15;7(10):204-20. doi: 10.4251/wjgo.v7.i10.204. Review.

13.

Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention.

Pabla B, Bissonnette M, Konda VJ.

World J Clin Oncol. 2015 Oct 10;6(5):133-41. doi: 10.5306/wjco.v6.i5.133. Review.

14.

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.

Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H.

BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z.

15.

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer.

Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, Muguruma K, Hirakawa K.

World J Gastroenterol. 2015 Sep 14;21(34):9966-73. doi: 10.3748/wjg.v21.i34.9966.

16.

Molecular phenotypes of colorectal cancer and potential clinical applications.

Kocarnik JM, Shiovitz S, Phipps AI.

Gastroenterol Rep (Oxf). 2015 Nov;3(4):269-76. doi: 10.1093/gastro/gov046. Epub 2015 Sep 3. Review.

17.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T.

Curr Oncol. 2015 Aug;22(4):e305-15. doi: 10.3747/co.22.2603.

18.

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.

Fu Y, Cruz-Monserrate Z, Helen Lin H, Chung Y, Ji B, Lin SM, Vonderfecht S, Logsdon CD, Li CF, Ann DK.

Sci Rep. 2015 Aug 20;5:13347. doi: 10.1038/srep13347.

19.

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market.

Davari M, Ashrafi F, Maracy M, Aslani A, Tabatabaei M.

Int J Prev Med. 2015 Jul 16;6:63. doi: 10.4103/2008-7802.161068. eCollection 2015.

20.

CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.

Camp ER, Ellis LM.

Clin Cancer Res. 2015 Aug 15;21(16):3578-80. doi: 10.1158/1078-0432.CCR-14-2900.

PMID:
26275951
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk